Since ERβ1 has been shown to decrease hypoxic signaling and the variants increase this signaling there could be a delicate balance between the ratios of ERβ1 and ERβ variants at different stages of TNBC progression to allow EMT and migration of tumor cells to form metastases and achieve chemotherapy resistance. The gene discussed is ESR2; the disease is neoplasm.